Abstract:Patients with cancer can develop metastatic disease after latency periods that range from years to decades. This latency can be explained by the occurrence of dormant micrometastatic tumor cells. The mechanisms that trigger dormant tumor cells to “be activated” and subsequently progress to an actively growing metastatic lesion and cause a late relapse are essentially unknown. However, recent data indicate that these mechanisms are largely influenced by the microenvironment of the secondary site. The main goal of our study was to evaluate the role of the lung microenvironment in the regulation of dormancy of neuroblastoma micrometastasis (MicroNB) and their progression toward macrometastasis (MacroNB). We hypothesize that factors present in the lung microenvironment inhibit the propagation of MicroNB cells, preventing them from forming overt lung metastasis. This study indeed shows that lung-derived factors significantly reduce the viability of MicroNB cells, induce a G0-G1 cell cycle arrest accompanied by a down-regulation of Cyclin D1 and decrease ERK and FAK phosphorylation in these cells. Utilizing biochemical separation methods, we isolated and identified the lung-derived factor responsible for the viability inhibitory effect to be mouse hemoglobin subunit beta-2 (HBB2). Purified human hemoglobin beta subunit (HBB) of 147 amino acid residues, which shares a 80% sequence identity to mouse HBB2, had comparable cytostatic/cytotoxic effects on neuroblastoma cells, while the alpha subunit of human hemoglobin was inactive. We identified the inhibitory active fragment of HBB to be a 15 amino acid sequence in the C-terminus of the protein. Treatment with this short inhibitory peptide significantly inhibits neuroblastoma local tumor growth and lung metastasis. HBB2 is thus a candidate for a new anticancer drug.

Supplemental Tables, Figures and Figure Legends from The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis

Supplemental Experimental Procedures from The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis

Data from The Beta Subunit of Hemoglobin (HBB2/HBB) Suppresses Neuroblastoma Growth and Metastasis

The Metastatic Microenvironment: A New Lung-Derived Factor Inhibits Neuroblastoma Lung Metastasis

C-110 the Metastatic Microenvironment

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation

A heterodimer of and hemoglobin chains functions as an innate anticancer agent

Supplementary Figure Legends from Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase II

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure Legends 1-2, Tables 1-2 from Comparison of Primary Neuroblastoma Tumors and Derivative Early-Passage Cell Lines Using Genome-Wide Single Nucleotide Polymorphism Array Analysis

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials and Methods, Supplementary Figure Legends, and Supplementary Tables 1 through 5 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Figure 2 from an Integrated Genomic Screen Identifies LDHB As an Essential Gene for Triple-Negative Breast Cancer

Supplementary Figure Legends 1-3, Methods, Tables 1-4 from Alterations of the HBP1 Transcriptional Repressor Are Associated with Invasive Breast Cancer

Supplementary Table 5 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Table 2 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Figure S1 from SSBP1 Suppresses TGFβ-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling

Supplementary Table 1 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Supplementary Data from A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models